| Mckenzie Melander, | |
|
3490 Lexington Ave N, Suite 305, Shoreview, MN 55126-8074 | |
| (651) 639-0942 | |
| Not Available |
| Full Name | Mckenzie Melander |
|---|---|
| Gender | Female |
| Speciality | Speech-language Pathologist |
| Location | 3490 Lexington Ave N, Shoreview, Minnesota |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1487048294 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 235Z00000X | Speech-language Pathologist | 9350 (Minnesota) | Primary |
| Provider Name | Associated Speech And Language Specialists Llc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1881636223 PECOS PAC ID: 1456663160 Enrollment ID: O20150709001670 |
News Archive
Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that over 70 percent of surveyed U.S. physicians indicate there is a high need for diabetes drugs with novel mechanisms of action versus 15 percent who say there is a high need for additional DPP-IV inhibitors.
Researchers from University of South Florida College of Medicine found a combination of antibiotics to be an effective treatment for Chlamydia-induced reactive arthritis, a major step forward in the management, and possibly cure, of this disease. Results of this study are published in the May issue of Arthritis & Rheumatism, a journal of the American College of Rheumatology.
BD (Becton, Dickinson and Company), a leading global medical technology company, along with Check-Points Health B.V., announced today that FDA 510(k) clearance was obtained for a molecular screening test for antibiotic-resistant carbapenemase-producing organisms on the fully-automated BD MAX System.
Anthera Pharmaceuticals, Inc., a privately held biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, announced today that it reached an agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for the Phase 3 clinical study named VISTA-16 (Vascular Inflammation Suppression to Treat Acute Coronary Syndrome - 16 Weeks) for its lead product candidate, A-002, an oral sPLA2 inhibitor, in combination with HMG-CoA reductase inhibitor, or statin, therapy for short-term (16-week) treatment of patients experiencing an acute coronary syndrome.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mckenzie Melander, 13632 Elkwood Dr, Apple Valley, MN 55124-9230 Ph: () - | Mckenzie Melander, 3490 Lexington Ave N, Suite 305, Shoreview, MN 55126-8074 Ph: (651) 639-0942 |
News Archive
Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that over 70 percent of surveyed U.S. physicians indicate there is a high need for diabetes drugs with novel mechanisms of action versus 15 percent who say there is a high need for additional DPP-IV inhibitors.
Researchers from University of South Florida College of Medicine found a combination of antibiotics to be an effective treatment for Chlamydia-induced reactive arthritis, a major step forward in the management, and possibly cure, of this disease. Results of this study are published in the May issue of Arthritis & Rheumatism, a journal of the American College of Rheumatology.
BD (Becton, Dickinson and Company), a leading global medical technology company, along with Check-Points Health B.V., announced today that FDA 510(k) clearance was obtained for a molecular screening test for antibiotic-resistant carbapenemase-producing organisms on the fully-automated BD MAX System.
Anthera Pharmaceuticals, Inc., a privately held biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, announced today that it reached an agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for the Phase 3 clinical study named VISTA-16 (Vascular Inflammation Suppression to Treat Acute Coronary Syndrome - 16 Weeks) for its lead product candidate, A-002, an oral sPLA2 inhibitor, in combination with HMG-CoA reductase inhibitor, or statin, therapy for short-term (16-week) treatment of patients experiencing an acute coronary syndrome.
› Verified 5 days ago
Kids Abilities, Inc Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 490 Highway 96 W, Suite 300, Shoreview, MN 55126 Phone: 651-451-3016 | |
Michele Marie Mcguire, M.S., CCC - SLP Speech-Language Pathologist Medicare: Medicare Enrolled Practice Location: 490 Highway 96 W, Suite 300, Shoreview, MN 55126 Phone: 651-451-3016 | |
Jennifer Ruth Elton, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 439 Carol Ln, Shoreview, MN 55126 Phone: 612-308-6132 Fax: 651-414-9339 | |
Jeanne L Gunvalson, M.S., CCC Speech-Language Pathologist Medicare: Medicare Enrolled Practice Location: 3490 Lexington Ave N, Suite 305, Shoreview, MN 55126 Phone: 651-639-0942 Fax: 651-639-1718 | |
Ms. Danielle S Leddy, SLP Speech-Language Pathologist Medicare: Medicare Enrolled Practice Location: 490 Highway 96 W, Suite 300, Shoreview, MN 55126 Phone: 651-451-3016 Fax: 651-481-7040 | |
Cassandra Araujo, SLP Speech-Language Pathologist Medicare: Medicare Enrolled Practice Location: Kids Abilities, Inc., 490 Highway 96 W, Shoreview, MN 55126 Phone: 651-451-3016 Fax: 651-481-7040 | |
Abby Husfeldt, MS, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 5985 Rice Creek Pkwy Ste 205, Shoreview, MN 55126 Phone: 612-888-4757 |